O'Neill K A, Liebman J M
Pharmaceuticals Division, Ciba-Geigy Corporation, Summit, NJ 07901.
Brain Res. 1987 Dec 1;435(1-2):371-6. doi: 10.1016/0006-8993(87)91628-3.
Injection of the specific N-methyl-D-aspartate (NMDA) antagonist, 3(2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid (CPP), into the frontal cortex of rats, induced hyperactivity characterized by unique episodic darting behavior. This behavioral profile contrasts sharply with the ataxia and hyperactivity seen after intracerebroventricular CPP and other NMDA antagonists.